Syndax Pharmaceuticals, Inc. - Common Stock (SNDX)

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer treatment

The company is dedicated to discovering and advancing novel drugs that aim to enhance patient outcomes by targeting specific mechanisms of cancer progression, particularly through immuno-oncology and epigenetic modulation. Syndax is actively engaged in multiple clinical trials to evaluate the efficacy and safety of its product candidates, which are designed to leverage the body's immune system and improve therapeutic responses in various malignancies. By fostering collaborations and pursuing a strategic pipeline, Syndax seeks to provide new options for patients battling cancer.